Citi Downgrades Boston Scientific, Warns Recovery Path Is 'Opaque'

Boston Scientific has been one of the market's steadiest "beat-and-raise" medtech names for years. That streak just hit a wall.

Citi downgraded the stock Thursday to Neutral from Buy, slashing its price target to $50 from $57. It's the eighth time this year Citi has trimmed its estimates on the company — a run that tells its own story about how 2026 has gone for Boston Scientific.

Shares are down 53% year-to-date, a brutal stretch for a company that spent much of the last decade compounding steadily higher. Citi analyst Joanne Wuensch says the reasons run deeper than any single quarter.

She points to a maturing, more competitive U.S. market for pulsed field ablation, a cooling left atrial appendage closure market, friction in the urology business, and — the freshest wound — an August cybersecurity attack the company is still working through.

"The time to resolution is opaque, investor patience has run thin, and we don't have a handle on the recovery path." — Joanne Wuensch, Analyst, Citi

The specifics matter here. Wuensch flagged Boston Scientific's Watchman device — its left atrial appendage closure implant — as facing proposed new clinical guidelines and pending reimbursement changes that could slow adoption. Management itself has guided for the closure market to shrink in the back half of 2026 and into 2027.

Adding pressure: Abbott is rolling out its next-generation Amulet device, a direct competitor that's expected to chip away at Boston Scientific's share in that category over the next several quarters.

On the ablation side, Wuensch modeled sales from Boston Scientific's Farapulse system declining 5.3% in the second half of this year and staying flat through 2027, as rival catheter launches intensify competition in pulsed field ablation — until Boston Scientific's own next-gen catheters arrive in late 2027.

The August cybersecurity incident hangs over all of it. Boston Scientific said independent assessments from CrowdStrike and other third-party experts haven't found evidence of ongoing threat activity, but the company is still working through order-fulfillment backlogs the attack created.

Not every analyst sees it the same way. Bernstein cut its price target to $60 from $72 on September 11 but kept an Outperform rating, and the broader Street still carries an average buy rating with a mean price target near $60.67, according to FactSet data — well above Citi's new $50 mark.

That split matters for investors trying to figure out what to do with the stock right now. The bull case still rests on Boston Scientific's underlying pipeline and market share; the bear case is that the cybersecurity fallout and competitive pressure could linger longer than the Street currently expects.

For anyone holding BSX, the near-term catalyst to watch is the next earnings call for concrete signs the cybersecurity disruption is resolved and order fulfillment is back to normal. A clean update there could stabilize sentiment even if growth stays muted.

New money looking at the name should wait for more clarity rather than trying to catch the falling knife — with eight downward estimate revisions this year, the burden of proof is on management now, not the bears.

Options traders should note implied volatility on BSX has stayed elevated since the cybersecurity disclosure in late August, a sign the market still isn't fully pricing in a clean resolution.

Keep an eye on reimbursement decisions tied to the Watchman device specifically. Any adverse ruling there would confirm the bear case; a favorable one could be the catalyst that finally stabilizes the stock.

Bottom line: Boston Scientific's growth story isn't dead, but Citi just told investors the "when" on recovery is genuinely unknown — and that uncertainty is the real risk right now, not the stock's price.